Lilly’s Alzheimer’s EXPEDITION3 Proves Positive For Biogen’s Anti-Amyloid At CTAD

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Lilly’s Phase III EXPEDITION3 results for solanezumab at CTAD contribute data to the Alzheimer’s field about the role of amyloid in disease progression, including the effect that other amyloid-targeting antibodies may have in ongoing clinical trials, such as Biogen’s Phase III candidate aducanumab.

Human brain illustrated with millions of small nerves - Conceptual 3d render

The presentation of Eli Lilly & Co.’s unsuccessful Phase III EXPEDITION3 clinical trial for solanezumab was supposed to be the main event on the first day of the Clinical Trials in Alzheimer’s Disease (CTAD) conference on Dec. 8 in San Diego, but updated results from the Phase Ib trial for Biogen’s earlier-stage amyloid-clearing antibody aducanumab stole the show after abstracts were leaked online.

Lilly has committed to sharing its data from the company’s now three failed Phase III studies for solanezumab and a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.